Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

被引:16
作者
Long, Yin [1 ]
Huang, Jue [1 ]
Liao, Jianguo [1 ]
Zhang, Dongbo [2 ]
Huang, Ziqi [1 ]
He, Xiaodong [1 ]
Zhang, Lei [1 ]
Vitale, Alessandro
Midorikawa, Yutaka
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou 510120, Peoples R China
关键词
hepatocellular carcinoma; conversion therapy; liver resection; unresectable; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; INFUSION CHEMOTHERAPY; SURGERY; LENVATINIB; SORAFENIB; CANCER;
D O I
10.3390/cancers15245878
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This study aimed to investigate the safety and long-term survival outcomes of salvage liver resection in patients with initially unresectable hepatocellular carcinoma (HCC) who had undergone triple combination conversion therapy (TACE/HAIC + TKIs + ICIs). While hepatectomy following conversion therapy exhibited elevated incidence rates of intra-abdominal bleeding, biliary leakage, post-hepatectomy liver failure, and Clavien-Dindo grade IIIa complications compared to pure hepatectomy, their safety profiles remained acceptable when appropriate medical interventions were administered. Patients with initially unresectable HCC, who successfully underwent conversion resection, demonstrated comparable overall survival (OS) and recurrence-free survival (RFS) to patients with initially resectable HCC.Abstract Triple combination conversion therapy, involving transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), has shown an encouraging objective response rate (ORR) and successful conversion surgery rate in initially unresectable hepatocellular carcinoma (HCC). However, the safety and long-term survival outcomes of subsequent liver resection after successful conversion still remain to be validated. From February 2019 to February 2023, 726 patients were enrolled in this retrospective study (75 patients received hepatectomy after conversion therapy [CLR group], and 651 patients underwent pure hepatectomy [LR group]). Propensity score matching (PSM) was used to balance the preoperative baseline characteristics. After PSM, 68 patients in the CLR group and 124 patients in the LR group were analyzed, and all the matching variables were well-balanced. Compared with the LR group, the CLR group experienced longer Pringle maneuver time, longer operation time, and longer hospital stays. In addition, the CLR group had significantly higher incidence rates of intra-abdominal bleeding, biliary leakage, post-hepatectomy liver failure (PHLF), and Clavien-Dindo grade IIIa complications than the LR group. There were no significant statistical differences in overall survival (OS) (hazard ratio [HR] 0.724; 95% confidence interval [CI] 0.356-1.474; p = 0.374) and recurrence-free survival (RFS) (HR 1.249; 95% CI 0.807-1.934; p = 0.374) between the two groups. Liver resection following triple combination conversion therapy in initially unresectable HCC may achieve favorable survival outcomes with manageable safety profiles; presenting as a promising treatment option for initially unresectable HCC.
引用
收藏
页数:13
相关论文
共 45 条
[1]  
[Anonymous], 2022, Zhonghua Gan Zang Bing Za Zhi, V30, P388
[2]   Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver [J].
Cleary, James M. ;
Tanabe, Kenneth T. ;
Lauwers, Gregory Y. ;
Zhu, Andrew X. .
ONCOLOGIST, 2009, 14 (11) :1095-1105
[3]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[4]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[5]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[6]   Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma [J].
Fan, J ;
Tang, ZY ;
Yu, YQ ;
Wu, ZQ ;
Ma, ZC ;
Zhou, XD ;
Zhou, J ;
Qiu, SJ ;
Lu, JZ .
DIGESTIVE SURGERY, 1998, 15 (06) :674-678
[7]   Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Ikeda, Masafumi ;
Zhu, Andrew X. ;
Sung, Max W. ;
Baron, Ari D. ;
Kudo, Masatoshi ;
Okusaka, Takuji ;
Kobayashi, Masahiro ;
Kumada, Hiromitsu ;
Kaneko, Shuichi ;
Pracht, Marc ;
Mamontov, Konstantin ;
Meyer, Tim ;
Kubota, Tomoki ;
Dutcus, Corina E. ;
Saito, Kenichi ;
Siegel, Abby B. ;
Dubrovsky, Leonid ;
Mody, Kalgi ;
Llovet, Josep M. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) :2960-+
[8]   Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial [J].
He, MinKe ;
Li, QiJiong ;
Zou, RuHai ;
Shen, JingXian ;
Fang, WanQiang ;
Tan, GuoSheng ;
Zhou, YuanMin ;
Wu, XiaoPing ;
Xu, Li ;
Wei, Wei ;
Le, Yong ;
Zhou, ZhongGuo ;
Zhao, Ming ;
Guo, Ying ;
Guo, RongPing ;
Chen, MinShan ;
Shi, Ming .
JAMA ONCOLOGY, 2019, 5 (07) :953-960
[9]   Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies [J].
Hyun, Myung Han ;
Lee, Young-Sun ;
Kim, Ji Hoon ;
Lee, Chan Uk ;
Jung, Young Kul ;
Seo, Yeon Seok ;
Yim, Hyung Joon ;
Yeon, Jong Eun ;
Byun, Kwan Soo .
HEPATOLOGY, 2018, 68 (03) :977-993
[10]   Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy [J].
Iacovelli, Roberto ;
Palazzo, Antonella ;
Procopio, Giuseppe ;
Santoni, Matteo ;
Trenta, Patrizia ;
De Benedetto, Angelina ;
Mezi, Silvia ;
Cortesi, Enrico .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) :929-938